Project Grant K99CA293168
Award Date
9/6/24
Completion Date
8/31/26
Dollars Obligated
$151K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $713,235 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to conduct a randomized controlled trial evaluating the efficacy of the MIND diet in improving cognitive function among breast cancer survivors experiencing cancer-related cognitive impairment. The 5-year project will enroll 200 breast cancer survivors and assess the impact of the...
This Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), will fund a pilot study to evaluate the associations of pre- and post-chemotherapy and -radiotherapy gut microbiome profiles with breast cancer recurrence and mortality. The $175,000 award will support the use of shotgun metagenome sequencing on 110 post-treatment stool samples from the Vietnam Breast Cancer Study, as well as an investigation of the impact of...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $678,399 to The University of Texas MD Anderson Cancer Center to conduct a prebiotic diet intervention study. The goal is to evaluate whether a prebiotic-enriched diet can enhance the gut microbiome and improve response to immune checkpoint inhibitor (ICI) therapy in patients with metastatic melanoma. The 5-year study will investigate the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will provide $402,401 to the University of Missouri System to conduct a pilot study on the feasibility and impact of a metacognitive strategy training (MCST) intervention for women with cancer-related cognitive impairment (CRCI) following breast cancer treatment. The study aims to examine the effects of MCST on cognitive performance, frontoparietal neural functioning, and functional...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $606,839 to Weill Medical College of Cornell University to study the role of microbiota amino acid metabolism in cancer. The project aims to identify gut microbes and their genes that deplete intestinal amino acids, and evaluate how they affect the tumor microenvironment and cancer progression. The 5-year project will combine bioinformatics, metabolomics,...
The National Cancer Institute (NCI) awarded a $425,573 Project Grant (CFDA 93.395 Cancer Treatment Research) to Magee-Womens Research Institute and Foundation located in Pittsburgh, Pennsylvania. The grant will fund a 2-year study (July 1, 2025 - June 30, 2027) to identify gut bacteria species, metabolites, and metabolic pathways associated with high mammographic breast density (MBD). The goal is to provide insights into modifiable factors that contribute to high MBD, which is a significant risk...
The National Cancer Institute (NCI) awarded a $142,295 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to President and Fellows of Harvard College, through its Harvard T.H. Chan School of Public Health division. The grant, which runs from May 1, 2025 to April 30, 2027, aims to identify gut microbial and metabolomic biomarkers of the relationship between ultra-processed foods and colorectal cancer risk, and to evaluate the feasibility and initial efficacy of a medically...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $426,425 to Baylor College of Medicine to conduct a pilot study examining the relationship between gut microbiome composition, metabolic dysfunction-associated steatotic liver disease (MASLD), and hepatocellular carcinoma (HCC). The key objectives of this 2-year study are to: 1) characterize baseline gut microbiome diversity associated with MASLD with and without HCC, 2)...
The Project Grant award of $300,000.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will support a study on the epidemiology of the gut-liver axis and its relationship to hepatocellular carcinoma (HCC) risk in a multiethnic liver cirrhosis cohort. The study aims to expand the existing Microbiome, Microbial Markers, and Liver Disease (M3LD) cohort by enrolling approximately 1,000 participants with liver cirrhosis, with a focus on...
This Project Grant award of $752,588 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports a 12-week randomized controlled trial to evaluate the effects of time-restricted eating on cancer-related fatigue among survivors of hematological malignancies. The study will recruit 96 eligible participants and assess patient-reported fatigue, circadian activity rhythm, and glucose metabolism at baseline, 6 weeks, and 12 weeks. The University of Maryland, Baltimore is...